comparemela.com

Latest Breaking News On - Valbiotis - Page 5 : comparemela.com

Valbiotis Provides an Update on Its Progress and Publishes Its Financial Report for the First Half of 2022

A cash position of €15.4 million at June 30, 2022. Financial visibility until the last quarter of 2023, excluding potential additional revenues. Continued execution of the strategic

United statesFrance generalEuropean regional development fundLaval university in quebec cityHealth scienceInstitute of nutritionPernod ricardResearch developmentYoung innovative companyPublic affairsResearch tax creditEuropean unionFoods at laval university in quebec cityInnovative companyUnited nations global compactLaval university

Valbiotis Announces Completion of Recruitment for the Phase II/III REVERSE-IT Clinical Study With TOTUM•63 Against Prediabetes, in Partnership With Nestlé Health Science

The last volunteer was enrolled in the REVERSE-IT study; recruitment of the 600 participants in this international, multicenter, randomized, placebo-controlled clinical study is complete. This

United statesNew zealandFrance generalSouth africaEuropean regional development fundHealth scienceResearch developmentYoung innovative companyHealth nutritionIndustrial affairsPublic affairsEuropean unionInnovative companyValbiotis boardNorth americanQuebec city

Valbiotis announces the major success of the Phase II HEART clinical study: the patented plant-based active substance TOTUM•070 proves its efficacy against hypercholesterolemia, a cardiovascular risk factor

This randomized, placebo-controlled Phase II clinical study with TOTUM•070 achieved its objective of reducing LDL cholesterol (primary endpoint) and confirmed the very good tolerance of this active

United statesBruxelles capitaleEuropean regional development fundEuropean heart networkAmerican heart associationResearch developmentYoung innovative companyIndustrial affairsPublic affairsEuropean unionInnovative companyGlobal health observatoryHead of developmentNorth americaInstitut de cancValbiotis board

Valbiotis Announces the Release of the Universal Registration Document

Regulatory News: Valbiotis (FR0013254851 ALVAL, PEA PME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases

France generalEuropean regional development fundLaval university institute of nutritionHealth scienceResearch developmentYoung innovative companyEuropean unionHealth canadaInnovative companyRegulatory newsUniversal registration documentFrench financial markets regulatorUnited nations global compactLaval university instituteFunctional foodsQuebec city

Valbiotis - Combined Shareholders General Meeting Held on May 5, 2022

Regulatory News: Valbiotis (Paris:ALVAL) (FR0013254851 ALVAL, PEA PME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases

Espace encanEuropean regional development fundYoung innovative companyEuropean unionResearch developmentInnovative companyRegulatory newsCombined shareholders meetingShareholder meetingQuebec cityValbiotis universal registration documentFrench financial markets regulator

vimarsana © 2020. All Rights Reserved.